JPMorgan keeps an Overweight rating on TG Therapeutics with a $28 price target after surveying a number of infusion centers to gauge expectations around Briumvi uptake over the mid to longer-term. The survey results suggest that Briumvi can build momentum in the early phase of launch before a permanent J-code is established, affirms shorter chair time being a key a driver of demand, and validates TG’s product pricing strategy, the analyst tells investors in a research note. The firm continues to see TG shares as undervalued in view of a $2B peak sales opportunity for Briumvi.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TGTX:
- TG Therapeutics management to meet with B. Riley
- TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75th Annual Meeting
- TG Therapeutics reports Q4 EPS (39c), consensus (26c)
- TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
- TG Therapeutics options imply 4.1% move in share price post-earnings